Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 13,679 Cr.
- Current Price ₹ 568
- High / Low ₹ 597 / 414
- Stock P/E 32.9
- Book Value ₹ 130
- Dividend Yield 0.40 %
- ROCE 18.8 %
- ROE 14.4 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | 3,510 | 3,813 | |
| 511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,292 | 2,892 | 3,175 | |
| Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 548 | 619 | 638 |
| OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% | 18% | 17% |
| 7 | -102 | -3 | -21 | 58 | 79 | 94 | 52 | 59 | |
| Interest | 6 | 9 | 7 | 6 | 31 | 49 | 22 | 19 | 22 |
| Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 80 | 126 | 149 |
| Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 539 | 525 | 526 |
| Tax % | 45% | 191% | 23% | 28% | 27% | 27% | 25% | 24% | |
| 14 | -12 | 149 | 163 | 266 | 337 | 407 | 401 | 401 | |
| EPS in Rs | 89.98 | -40.20 | 951.96 | 937.73 | 11.99 | 15.14 | 16.95 | 16.65 | 16.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% | 13% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 15% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 16% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.31 | 0.31 | 0.35 | 44 | 44 | 48 | 48 |
| Reserves | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,568 | 3,091 |
| 147 | 483 | 51 | 66 | 502 | 490 | 102 | 144 | |
| 108 | 222 | 220 | 524 | 638 | 627 | 609 | 1,337 | |
| Total Liabilities | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
| 104 | 119 | 86 | 138 | 664 | 646 | 678 | 1,812 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 12 |
| Investments | 0 | 13 | 0 | 120 | 614 | 796 | 1,290 | 1,100 |
| 225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 | 1,697 | |
| Total Assets | 329 | 600 | 596 | 1,353 | 2,204 | 2,546 | 3,326 | 4,620 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 65 | 22 | 172 | 297 | 130 | 508 | 442 | 651 | |
| -18 | -16 | -81 | -158 | -896 | -326 | -677 | -508 | |
| -21 | 136 | -132 | 233 | 333 | -66 | 288 | -83 | |
| Net Cash Flow | 25 | 143 | -40 | 373 | -433 | 115 | 52 | 60 |
| Free Cash Flow | 48 | 16 | 151 | 272 | 111 | 497 | 412 | 606 |
| CFO/OP | 196% | 34% | 96% | 128% | 60% | 125% | 110% | 129% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 127 | 108 | 97 | 102 | 91 | 97 | 102 |
| Inventory Days | ||||||||
| Days Payable | ||||||||
| Cash Conversion Cycle | 60 | 127 | 108 | 97 | 102 | 91 | 97 | 102 |
| Working Capital Days | -7 | -5 | 45 | 11 | 41 | 27 | 39 | 5 |
| ROCE % | 37% | 55% | 46% | 33% | 29% | 25% | 19% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| $1M+ Clients Count |
|
|||||
| Active Client Relationships Count |
||||||
| Total Employees Count |
||||||
| $25M+ Strategic Clients Count |
||||||
| Top 20 Customer Revenue INR Mn |
||||||
| Revenue per Employee USD |
||||||
| Net Revenue Retention % |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Indegene schedules investor meetings with MFS, ASK, Mirae on 24 Aug 2026; Goldman Sachs and Seven Canyon on 25 Aug 2026.
-
Announcement Under Regulation 30 (LODR) - Update On Material Litigation
- Indegene subsidiary nearing TCPA class-action settlement; maximum fund about USD 4.72 million, subject to court approval.
- Transcript Of The 28Th Annual General Meeting Held On August 13, 2026
-
Announcement under Regulation 30 (LODR)-Change in Directorate
- Shareholders approved appointment of Ms. Jill Mary De Simone as Independent Director for 3 years from January 22, 2026.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 28th AGM on 13 Aug 2026: all resolutions passed; scrutinizer’s report and voting results submitted.
Annual reports
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026TranscriptAI SummaryPPT
-
May 2026Transcript PPT REC
-
Apr 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT
-
Oct 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Mar 2025TranscriptAI SummaryPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptPPTREC
Business Overview [1]
The company is a strategic operating partner to the global life sciences industry, supporting commercial, medical, R&D, and safety operations across the product lifecycle. It combines deep life sciences expertise with AI-enabled platforms, data analytics, and governed operating models, servicing the world’s top 20 biopharma companies. Its capabilities span five key areas: Discovery & Evidence, Regulatory & Compliance, Commercial Launch, Content & Engagement, and Patient & Outcomes.